Respiratory eHealth, remote monitoring and data management company Adherium (ASX: ADR) has announced that it has received US FDA clearance to market application connecting GSK’s Ellipta inhaler users with its new Hailie sensor with physiological parameters for monitoring Asthma and COPD medication use.
CEO Rick Legleiter said, “Executing our strategy and once again delivering on our product roadmap milestones, we continue to demonstrate Adherium is the global partner of choice for remote patient monitoring.
“The FDA’s clearance to connect Ellipta inhaler users with our new, next-generation Hallie platform represents another major step forward in our drug agnostic strategy. In addition, this further broadens the pathway for doctors and hospital groups in the US to access reimbursement for remote monitoring of patients prescribed Asthma and COPD medications on our path toward building a sustainable, cash flow positive business.”
The new Hailie sensor captures physiological parameters, including inhalation duration, volume, and peak inhalation flow. It gives patients and doctors immediate, real-time feedback.